Universal Donor Expanded TGF-beta-imprinted NK Cells Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since June 2026

Also known as: Allogeneic TGFBi Expanded NK Cells, UD TGF-betai NK Cells, Universal Donor TGF-beta Imprinted Expanded NK Cells

Pipeline

Phase 1/2: 1

Top Sponsors

Margaret Gatti-Mays1

Indications

Anatomic Stage IV Breast Cancer AJCC v81
HER2-Negative Breast Carcinoma1
Breast Cancer1
Cancer1

Columbus, Ohio1 trial

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.